Patent details

LUC00133 Product Name: pegvaliase (Palynziq)

Basic Information

Publication number:
LUC00133
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP087547170
Legal Status:
Inactive
Application number:
LUC00133
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/19/1362
Marketing Authorization Type:
Marketing Authorization Date:
08/05/2019
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
14/10/2019
First Marketing Authorization date:
08/05/2019
Grant date:
16/07/2020
Activation date:
Publication date:
16/10/2019
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
23/05/2033
SPC Extension Expiration:
23/05/2033
Rejection date:
Withdrawal date:

Owner

From:
14/10/2019
 
 

Name:
BioMarin Pharmaceutical Inc.
Address:
105 Digital Drive, Novato, CA 94949, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
14/10/2019
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2019/12
Publication date:
07/11/2019
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2020/09
Publication date:
04/08/2020
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
31/05/2028
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
14/10/2019 General Document 53
16/07/2020 Certificate 1
16/07/2020 Outgoing Correspondence 1
14/10/2019 General Document 3
16/10/2019 Outgoing Correspondence 1
14/10/2019 Application Form 4
16/07/2020 Publication 1
14/10/2019 General Document 2
16/10/2019 Publication 1